INTRODUCTION
The incidence of melanoma is increasing at the second highest rate of all human cancers, and metastatic disease is generally fatal (1, 2) . Metastatic melanomas are typically resistant to radiation and chemotherapy (1, 3) , suggesting that some melanomas maintain an anti-apoptotic phenotype. Currently, there is a critical need for the development of therapeutic agents that could target aberrant survival pathways in metastatic melanomas. Recently, the role of the transcription factor nuclear factor kappa B (NFjB) in protecting melanoma cells from apoptosis has received considerable interest. We (4, 5) and others (6, 7) have shown that NFjB is constitutively activated in metastatic melanoma cells in culture.
The mammalian NFjB family contains five members; p105/ p50, p100/p52, RelA, RelB and cRel that share a highly conserved 300 amino acid Rel homology domain with dimerization, nuclear localization and DNA binding regions (8) . RelA, RelB and cRel also contain transcriptional transactivation domains that directly activate expression of over 100 genes, including many critical in apoptosis. RelA, cRel, p105/ p50 and p100/p52 can form multiple homo-and hetero-dimers, each of which has distinct DNA binding site specificities and affinities (9) (10) (11) (12) (13) . Upon activation, these dimers translocate to the nucleus where they bind DNA at NFjB sequences found in the promoters of target genes (8, (13) (14) (15) .
The dimeric composition of NFjB is critical to the specificity of gene transactivation. cRel containing NFjB dimers can transactivate different genes than those dimers containing RelA (15, 16) . For example, RelA inhibits expression of the TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4/DR5 and up-regulates cIAP1, cIAP2 and caspase-8. Conversely, c-Rel enhances expression of DR4/DR5, Bcl-X and inhibits cIAP1, cIAP2, and survivin after TRAIL treatment. Whether NFjB functions as an inhibitor or activator of apoptosis depends on the relative levels of RelA and c-Rel subunits (15) . Transcriptionally inactive nuclear NFjB in resting cells consists of homodimers of either RelA or p50 complexed with the histone deacetylase-1 (HDAC-1). RelA homodimers complexed with HDAC-1 have low DNA binding affinity, but p50 homodimers lacking transactivation domains bind DNA with high affinity and are transcriptionally repressive (17) .
NFjB regulation is mediated through multiple kinase pathways that phosphorylate precursors (p105, p100), inhibitory proteins (IjB) and RelA (17) (18) (19) . The three major IjB proteins have distinct binding affinities for the various homoand hetero-dimeric NFjB complexes (8) . IjB-a preferentially inhibits p50 heterodimers containing RelA and to a lesser extent those with cRel. Unphosphorylated IjB-b preferentially inhibits RelA homo-and hetero-dimers but phosphorylated IjB-b preferentially binds cRel dimers. IjB-e is associated with cRel and RelA, but not with p50 (8, 14, 16, 20, 21) .
In general, IjB-a is more effective in inhibition of nuclear NFjB complexes than IjB-b, but is rapidly degraded by the proteasome in response to stimuli (22) . IjB-b is less sensitive to stimulus dependent degradation (13) . Upon activation, IjB-e protein is also degraded with slow kinetics by a proteasome-dependent mechanism that appears to regulate a late, transient activation of a subset of genes, regulated by RelA/cRel complexes (16) .
Activation of NFjB leads to the immediate transcriptional transactivation of its inhibitors p100, p105 and IjB-a. Induction of newly synthesized inhibitors by NFjB functions as an immediate negative feedback mechanism that leads to sequestration of the transactivating NFjB as inactive cytoplasmic complexes. Induction of IjB-a in particular facilitates export of activated RelA-p50 heterodimeric complexes from the nucleus thereby terminating NFjB function (8, 16, 20, (23) (24) (25) (26) .
The specificity of NFjB signaling is not only fine tuned by its homo-and hetero-dimeric composition. There are multiple levels of regulation of NFjB activation, including phosphorylation and acetylation of NFjB proteins, phosphorylation and acetylation dependent recruitment of transcriptional coactivators and subsequent modification of nucleosomal histones (13) .
The expression, localization and signaling of specific NFjB subunits and inhibitors has been studied in detail in immune cells and in malignancies (13) . NFjB expression and signaling in normal melanocytes, benign naevi and malignant melanoma however is not well detailed. Elevated inhibitor of kappa kinase (IKK) activity, enhanced degradation of IjB-a and constitutive activation of NFjB have been shown in Hs294T melanoma cells (6, 7, 27) and NFjB activity was shown to correlate with angiogenesis and metastasis of human melanoma in a nude mouse model (28) . We have shown that NFjB DNA binding mediated by RelA-p50 dimers is constitutively elevated in human metastatic melanoma cell cultures and that nuclear and cytoplasmic levels of RelA protein are elevated in melanoma cells (4) . RelA RNA expression is also elevated in metastatic melanoma relative to normal human melanocyte cultures (4, 5) .
To investigate the expression pattern of NFjB family members in human melanocytic cells of normal skin, benign intradermal naevus and metastatic melanoma tissues, we analyzed 60 human biopsies (20 normal skin, 20 benign naevus and 20 metastatic melanoma) for expression of RelA, cRel, p105/p50, and the inhibitory proteins IjB-a, IjB-b and IjB-e. We also examined the expression of an activated form of RelA, serine 529-phosphorylated RelA.
MATERIALS AND METHODS

Immunohistochemistry
All metastatic melanoma and benign intradermal naevus diagnoses on tissues used in these studies were made independently by pathologists not involved in this study. Normal skin biopsies were obtained from amputations. All of the naevi were classified as benign, no junctional or dysplastic naevi were included in this analysis. Formalinfixed, paraffin-embedded sections from normal skin, benign naevus and metastatic melanoma biopsies were placed on capillary gap slides, deparaffinized with Histoclear and rehydrated through decreasing concentrations of isopropyl alcohol. Mounted tissues were immersed in 0.25% KMnO 4 for 10 min, rinsed in water, immersed in 5% oxalic acid until cleared (<1 min) and rinsed in water prior to staining to bleach melanin (29) . All antibodies used were determined to be compatible with the bleaching process. Avidin-biotin complex (ABC) immunoperoxidase reactions were performed using an Immunotech 500 automated immunostainer (Ventana Systems Inc., Tucson, AZ, USA) according to the manufacturer's instructions. Briefly, the automated steps included antigen retrieval by steam, blockage of endogenous peroxidase with 3% hydrogen peroxide and incubation with the primary antibody. The reaction was followed by a biotinylated goat-antimouse IgG secondary antibody and then an avidin-biotin peroxidase complex. The chromogen was diaminobenzidine for all reactions. Negative controls, in which slides were treated as above, with the exception of the addition of the primary antibody, were run simultaneously. Identification of melanocytic cells in human skin, naevus and melanoma sections was done by use of initial hematoxylineosin stain (30) . Melanocytes are recognizable as randomly dispersed cells, wedged between the basal cells within the epidermis. Melanocytes have dark-staining nuclei and largely as a result of retraction or shrinkage, clear cytoplasm. Not all clear cells in the sections examined were melanocytes. Occasionally, basal keratinocytes show some shrinkage artifact, in these cases intercellular bridges were used to differentiate basal keratinocytes with cytoplasmic clearing from melanocytes. In instances, where it was not possible to differentiate between keratinocytes and melanocytes, the cells in question were not scored. Only melanocytic cells, as determined by the dermatopathologist involved in this study, were included in the analysis.
Statistical Analysis
Cells were scored by intensity of immunoperoxidase staining as negative (0), or positive with a grade of 1+, 2+ or 3+. Cells of melanocytic origin scored as 2+ or 3+ were rated with high positivity and the mean ± SD was calculated using Prism GraphPad for each group: skin, naevus or metastatic melanoma. Student's t-test and one-way analysis of variance with the Bonferroni Multiple Comparison Test and were performed to determine significant differences (defined as P < 0.05).
Antibodies
Antibodies directed against specific NFjB proteins were obtained from Nancy Rice (NIH Bethesda, MD, USA), p105/p50 (PAb-1157, 1:5000); Rockland Immunochemicals (Gibertsville, PA, USA), serine 529-phosphorylated RelA (PAb-200-3165, 1:500); Chemicon International (Temecula, CA, USA), nuclear localization specific RelA (Mab-3026, 1:2000); Santa Cruz Biotech (Santa Cruz, CA, USA), RelA (MAb-sc-8008, 1:10 000), cRel (MAb-sc-6955, 1:250) IjB-a (PAb-sc-371, 1:2000) Ij-b (PAb-sc-945, 1:500), Ij-e (PAb-sc 7155, 1:500).
RESULTS
RelA Expression is Elevated in Naevus and Melanoma Biopsies
The percentages of melanocytic cells with high positive staining for each group; normal skin melanocytes, benign intradermal naevi and metastatic melanoma are shown in greater heterogeneity both within and among biopsies, significantly higher percentages of melanocytic cells from naevus and metastatic melanoma biopsies had high positivity for RelA compared with melanocytes in normal skin biopsies (P < 0.05), as shown in Figs 1A and 2 (1A, 1B, 1C) .
Phosphoserine-529 RelA is Elevated in Naevus and Melanoma Biopsies and is Both Cytoplasmic and Nuclear in Metastatic Melanomas
Using primary antibodies specific for phosphoserine-529 RelA (pRelA), we found that significantly higher percentages of melanocytic cells from naevus and metastatic melanoma biopsies had high positivity for pRelA compared with melanocytes in normal skin biopsies (P < 0.05), as shown in Fig. 1B . One hundred percent of the naevus and 80% of the melanoma biopsies expressed high levels of phosphoserine-529 RelA, as shown in Figs 1B and 2 (2B, 2C) . In contrast, only 10% of the normal skin biopsies had melanocytes that expressed high (2+) levels of this phosphorylated form of RelA [Figs 1B and 2 (2A)].
Nuclear expression of phosphoserine-529 RelA was significantly higher in melanoma than in naevi (P < 0.001). As shown in Fig. 2 (2B) , expression of phosphoserine-529 RelA was almost exclusively cytoplasmic in naevi. However, 40% of the melanoma biopsies also expressed high nuclear levels of phosphoserine-529 RelA [ Fig. 2 (2C) ].
The Nuclear Localization Signal of RelA is Unmasked in Melanomas
As shown in Figs 1C and 2 (3A, 3B, 3C ), the percentage of cells with high positivity for the unmasked nuclear localization In the normal skin biopsies, melanocytes at the dermal border are indicated by black arrows. In the skin biopsies, keratinocytes and dendritic cells in the upper epidermal layer are also visible. In the melanoma biopsies, infiltrating lymphocytes are visible. However, only cells of melanocytic origin were included in the analysis. The primary antibodies used were panels (1) Anti-RelA antibody, (2) Anti-phosphoserine-529 specific RelA antibody, (3) Anti-nuclear localization signal specific RelA antibody (NLS RelA), (4) Anti-IjB-alpha antibody, 40· magnification. signal (NLS) domain of RelA was significantly higher in melanoma cells than in melanocytes from either skin or naevus biopsies (P < 0.001). Furthermore, 3+ levels of this form were detected exclusively in metastatic melanomas (data not shown).
Expression of IjB Proteins is Increased in Both Naevi and Melanomas; IjB-b Expression is Raised to Equivalent Levels, But IjB-a is Higher While IjB-e is Lower in Naevi than in Melanomas
As shown in Figs 1D and 2 (4A, 4B, 4C) , both naevus and melanoma biopsies had a greater percentage of melanocytic cells that showed high positivity for the inhibitory protein IjB-a than melanocytes in normal skin biopsies (P < 0.001 and P < 0.05, respectively). However, the percentage of cells with high positive staining with IjB-a antibodies was significantly reduced (P < 0.05) in melanomas relative to naevi and there was also a loss in the intensity of immunostaining in melanomas compared with naevi (data not shown). Furthermore, all of the melanoma biopsies that showed high nuclear expression of phosphoserine 529-RelA also expressed low levels of the inhibitor IjB-a. As seen in Fig. 1E , IjB-b was elevated equally in naevi and in melanomas. However, as shown in Fig. 1F , IjB-e was elevated to a greater extent in melanomas than in naevi.
cRel is Increased in Melanomas and Correlates with Increased IjB-e Expression
As shown in Fig. 1G , the percentage of melanoma cells showing high positivity for cRel was significantly higher in melanomas than the percentage of melanocytes either from naevus or from normal skin biopsies (P < 0.001). About 60% of the melanoma biopsies exhibited high levels of cRel in comparison with 0% of normal skin biopsies and 15% of naevus biopsies [ Fig. 3 (1A, 1B, 1C) ]. There was also a shift in the percentage of cells with 2+ to those with 3+ in the intensity of cRel immunostaining in melanomas compared with naevi (data not shown). Of the melanoma biopsies with cells that showed high positivity for cRel, 80% also expressed high levels of IjB-b, 50% expressed high levels of Ij-Be, 90% expressed high levels of either IjB-b or Ij-Be and 50% expressed high levels of both of these inhibitory proteins. While 90% of the melanoma biopsies were negative for nuclear cRel, one had less than 1% of cells with nuclear cRel expression, but one had 30% nuclear cRel staining. In this biopsy, 90% of the cells had low expression of IjB-b and 70% had low IjB-e. p50 was highly expressed in all cells in normal skin, benign naevus and metastatic melanoma biopsies. Because intercellular bridges could not be unambiguously determined in the normal skin tissues stained with p50 antibodies, statistical analysis was not performed and p50 data were presented qualitatively. Cytoplasmic p50 was also highly expressed in the metastatic melanoma biopsies, but the nuclear p50 appeared to be less intense, as shown in Fig. 3 (4A, 4B, 4C) . Negative controls, which lacked the relevant primary antibody, were run simultaneously, and as shown in Fig. 3 (5A , 5B, 5C), cells were negative for immunoperoxidase staining.
DISCUSSION
Studies previously conducted in tissue culture showed that RelA expression and DNA binding was higher in metastatic melanoma cells than in melanocytes (4) . In this study, we found that the melanoma cells in the majority of patient biopsies also had significantly higher expression of RelA than melanocytes found in normal epidermal tissues. Surprisingly, we also found that RelA expression was significantly higher in the melanocytes found in benign intradermal naevus biopsies compared with melanocytes found in normal epidermal skin tissues.
It is interesting to note that in two of the melanoma biopsies, the melanoma cells had a distinctly spindled morphology and expressed low levels of RelA (0/+1) in contrast to the other melanoma biopsies. Desmoplastic malignant melanoma (DMM) is a rare variant of malignant melanoma histologically distinguishable by its spindle cells. Although distant metastases do develop, DMM typically presents with nodal metastasis less frequently than other forms of melanoma, and has a better prognosis. DMM has a tendency for local recurrence after apparently complete surgical excision, but this can be dramatically reduced by adjuvant radiation therapy (31) .
We could speculate that alterations in RelA expression may be correlated with melanomas that arise in a naevus, but perhaps not those that arise independently. Future analyses of primary melanomas by depth, association with a naevus and classification (superficial spreading, nodular, desmoplastic, lentiginous, accral) may help to clarify this. Because RelA is known to protect cells against apoptosis from radiation and chemotherapy (32) (33) (34) (35) (36) , RelA expression levels may help in predicting whether a particular melanoma will respond to radiation therapy. These observations warrant further investigation.
We also found that serine-529 phosphorylated RelA is elevated in melanoma and naevus biopsies relative to melanocytes from normal skin. However, significantly more of this activated form of RelA accumulated in the nuclear compartment of melanomas than naevi. In addition, we found a significant increase in expression of RelA with an unmasked NLS in melanoma biopsies relative to melanocytes in both normal skin and naevus biopsies. Dhawan et al. also reported that NFjB activation, which they measured as expression of the unmasked NLS, was associated with Akt/ PKB in melanoma and dysplastic naevus (37) . They further reported that inhibition of PI3 kinase and Akt corresponded with a decrease in NFjB-luciferase reporter assays but showed no effect on IKK activity (37) . Akt has been shown by others to activate the transactivation potential of RelA without increasing IjB-a degradation or nuclear localization of RelA (38) (39) (40) . Recent studies have shown that Akt is a downstream target of NFjB and that nuclear translocation of RelA and increased NFjB DNA binding activity precede Akt phosphorylation (38) . Furthermore, over-expression of RelA causes an increase in Akt mRNA and protein and stimulates phosphorylation of Akt (38, 41) .
Multiple kinase pathways phosphorylate NFjB inhibitory proteins and precursors as well as RelA. The catalytic subunit of protein kinase A phosphorylates RelA at serine-276 (19, 42) and PKCf phosphorylates RelA at serine 311 (43) . These phosphorylation events stimulate the transactivation potential of RelA by facilitating recruitment of the coactivators CBP/p300 (17, 19, 38, 41, 43) . It has been proposed that Akt also stimulates the transactivation potential of RelA by CBP/p300 interactions (44, 45) . The IKK complex controls stimulus dependant degradation of IjB-a (18, (46) (47) (48) and RelA is simultaneously phosphorylated at Serine-536 (42) . IjB-a is constitutively phosphorylated in vivo by casein kinase II (CK2) at serine-293, which alters its intrinsic stability, plays a role in its constitutive turnover and mediates rapid degradation of free IjBa (48) (49) (50) (51) (52) (53) (54) . RelA is also phosphorylated at serine-529 by CK2 (55) .
It is well-established that one of the first genes to be transcriptionally transactivated by NFjB is its inhibitor IjBa (13, 14, 32, 34) . This induction functions as a negative feedback mechanism to down-regulate NFjB activity (13, 14, 32, 34) . We found that expression of the inhibitory protein IjB-a is elevated in naevus and melanoma biopsies compared with normal skin melanocytes. We postulate that this may reflect enhanced NFjB transcriptional activity in both naevi and melanomas. However, we also found that IjB-a expression was significantly reduced in melanoma relative to naevus biopsies.
These results suggest that increased expression and phosphorylation of RelA occur at the stage of the benign intradermal naevus, but that there may be sufficient levels of the inhibitory protein IjB-a to sequester RelA in the cytoplasm. In contrast, the melanomas also have high RelA expression and high activation to the phosphoserine-529 form of RelA, but have reduced IjB-a expression. The increased nuclear levels of phosphoserine-529 RelA in metastatic melanomas is biologically consistent with both the observed loss in IjB-a expression and the increase in expression of RelA with the unmasked NLS.
NFjB activation has also been reported to transactivate cRel (8) . In the current study, we found that expression of cRel is also elevated in melanoma cells of metastatic biopsies in comparison with melanocytes of both naevus and skin biopsies. However, the cRel was retained in the cytoplasmic compartment in the melanomas. In addition to decreased IjB-a expression in melanomas, we also found significantly elevated IjB-e expression in melanoma compared to naevus biopsies. IjB-e primarily regulates cRel nuclear translocation (8, 13, 16) and its increased expression in melanomas may explain in part, the predominantly cytoplasmic pattern of cRel expression in melanomas. We also found an equivalent increase in IjB-b expression in melanocytic cells of both naevus and metastatic melanoma biopsies.
In sharp contrast to IjB-a, the inhibitory activity of IjB-b is enhanced by phosphorylation of its C-terminal PEST domain. Basal phosphorylation at consensus CK2 sites of IjB-b converts it to a strong inhibitor of DNA binding and is required for the efficient formation of IjB-b-cRel complexes (56) (57) (58) . This may also contribute to the cytoplasmic retention of cRel in melanomas. Therefore we propose that in addition to other kinases such as IKK and Akt, CK2 may also play a contributory role in deregulation of NFjB activity in some melanomas.
Over-expression of RelA may be an early transitional event between melanocytes at the dermal-epidermal junction and those forming a benign intradermal naevus. Under normal circumstances, NFjB nuclear localization is regulated by IjB-a. Signaling mediated by RelA can also be balanced by activation of cRel containing dimers. Generally RelA promotes anti-apoptotic and cRel promotes pro-apoptotic signals. In melanomas however, loss of IjB-a, accumulation of nuclear RelA and absence of nuclear cRel suggest that the NFjB balance in some melanomas may be tipped in favor of constitutive NFjB signaling mediated by RelA. While other pathways including INK4a/ARF (2, 59), PKC (43, 60) , PKA (19, 61) , Ras (62) and FGF (63, 64) may be involved in the transition to a malignant melanoma, RelA signaling could establish a corps of anti-apoptotic proteins that protect melanomas from death signals as well as radiation and chemotherapy. Recent advances in the development of drugs that down-regulate NFjB signaling may therefore provide potential adjuvants to conventional therapies in some melanomas.
